Teva Pharma (TEVA) – Company Press Releases
-
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
-
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
-
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) T
-
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
-
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
-
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
-
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
-
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Ente
-
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China
-
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
-
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
-
Teva Canada Named by Forbes as No. 1 Canadian Employer in Drugs & Biotechnology Industry
-
Immuneering Announces Participation in February Investor Conferences
-
Teva Reports Growth in Fourth Quarter and Full Year 2023
-
Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy
-
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024
-
Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
-
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
-
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
-
Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference
-
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.
-
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
-
Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
-
Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business
-
Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual Meeting
-
UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry
-
Teva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care Program
-
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
-
Teva Leverages Market-leading Temperature and Theft Tracking from FourKites to Deliver Critical Medicines Around the World
-
Teva Leverages Market-leading Temperature & Theft Tracking from FourKites to Deliver Critical Medicines Around the World
-
Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023
-
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
-
Teva Announces Changes to Executive Management Team
-
Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
-
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congr
-
Teva Settles Price Fixing Charges With U.S. DOJ
-
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
-
Teva Reports Second Quarter 2023 Financial Results
-
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development
-
Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023
-
Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chr
-
Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patie
-
Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims
-
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
-
Teva Concludes Nationwide Opioids Settlement Agreement
-
Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management
-
Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023
-
Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychia
-
Teva Launches New “Pivot to Growth” Strategy
Back to TEVA Stock Lookup
